Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-14

Study Completion Date

2022-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Describe the immune response of patients affected by SARS-CoV-2, including an assessment of the types of antibodies elicited by the infection, specifc antibody titers for the different isotypes, evolution of the antibody response over time, protective efficacy and immune correlates of protection.

investigate genetic determinants of Covid-19 and of the imune response to this condition.

Finally, the study will investigate secondary infection rate and its determinants among household contacts of Covid-19 patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ImmuneSense™ COVID-19 Cross-Reactivity Study

NCT05112874

Coronavirus Disease SARS-CoV-2 Infection

WITHDRAWN

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

NCT06580639

Tuberculosis Immunologic Activity Alteration

RECRUITING

Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis

NCT04930978

COVID-19 Respiratory Infection Pulmonary Tuberculoses

RECRUITING

COVID-19: Herd Immunity Study in the Czech Republic

NCT04401085

COVID SARS-CoV 2

COMPLETED

ImmuneSense COVID-19 Variant Study

NCT05054088

Covid19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of the study is to describe the immune response to the SARS-CoV-2 virus among patients with confirmed Covid-19 disease in terms of antibody levels, differences in response related to epidemiologic and clinical characteristics, duration of the antibody response and protective efficacy.

Of particular interest is the demonstration of seroconversion with neutralizing antibodies, their duration during a follow-up of two years and their ability to prevent subsequent infections and disease. If antibodies are demonstrated to protect against subsequent infections and that protection is long-lasting, this can be instrumental for the reincorporation of immune individuals into normal life and economic activities.

Additional secondary objectives include determination of population-prevalence of past infection and assessment of genetic determinants of the immune response and the clinical presentation of the disease. Finally, we will investigate secondary transmission in a sample of household contacts of Covid-19 cases.

This study will provide important information to define the use of specific types of antibodies and their potential utility for diagnosis, ascertainment of previous exposure and acquired immunity. The effort is being conducted by the Caja Costarricense de Seguro Social, the Costa Rican Ministry of Health and the Agencia Costarricense de Investigaciones Biomédicas (ACIB), in collaboration with the US National Cancer Institute, the US National Institute of Allergy and Infectious Diseases and the German Cancer Research Center and will be supervised by the Ethical Committee of the CCSS according to local regulations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active / Recovered Cases

Active Cases:

Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.

Most of the cases of Covid-19 are treated at CCSS hospitals or clnics.

Recovered cases:

Are subjects previously diagnosed with Covid-19 via a positive PCR test who were considered recovered because they had two consecutive negative PCR tests.

1. Characterize the immune response after infection with SARS-CoV-2

Intervention Type GENETIC

1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Community control group

The community control group will be frequency-matched on age, sex and area of residence. Two controls per case will be selected as follows

1. Characterize the immune response after infection with SARS-CoV-2

Intervention Type GENETIC

1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Household survey

Are a household contact of a person diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.

A household will be defined as a group of persons living together who share a kitchen. To be considered eligible for inclusion a contact must have spent at least one night per week in the living area since onset in the index case.

1. Characterize the immune response after infection with SARS-CoV-2

Intervention Type GENETIC

1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1. Characterize the immune response after infection with SARS-CoV-2

1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Potential participants will be deemed eligible if they are:

* Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020
* Able to communicate with study personnel (or parents for children under 12);
* Able and willing to provide a blood sample (or parents);

Potential participants will be deemed eligible if they are:

* Able to communicate with study personnel (or parents for children under 12);
* Able and willing to provide a blood sample (or parents);
* Not planning to move out of the study area in the next 12 months

Exclusion Criteria

Potential participants will be excluded or deferred from enrollment if:

* They are in critical clinical condition precluding enrollment at the discretion of the treating clinicians (deferral)
* The clinician determining eligibility in agreement with the principal investigator considers that there is a reason that precludes participation;
* The participant or her parent/legal guardian, as applicable, does not have an identification document.

Enrollment of active cases Most of the cases of Covid-19 are treated at CCSS hospitals or clnics, where the it is a disease of mandatory reporting. Personnel of the Social Security or Ministry of Health will inform the potential participant case about the study and ask if they are willing to be contacted by study personnel to receive further information. The intention is to recruit all cases with the disease registered in Costa Rica.

Enrollment of recovered cases

Potential participants will be excluded or deferred from enrollment if:

* They have incapacitating or other conditions impeding participation as determined by the study team
* The participant or her parent/legal guardian, as applicable, does not have an identification document.

Minimum Eligible Age

6 Months

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No